Hkon Reikvam

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/210249/hakon-reikvam-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101 papers	1,491 citations	24 h-index	33 g-index
119 ext. papers	1,915 ext. citations	4.1 avg, IF	4.9 L-index

#	Paper	IF	Citations
101	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis.. *Current Oncology*, **2022**, 29, 2193-2198	2.8	
100	Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.. *Frontiers in Medicine*, **2022**, 9, 819465	4.9	0
99	Thrombosis and thrombocytopenia after HPV vaccination. *Journal of Thrombosis and Haemostasis*, **2021**,	15.4	5
98	Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. *Case Reports in Critical Care*, **2021**, 2021, 6676407	1	1
97	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. *Cells*, **2021**, 10,	7.9	1
96	Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
95	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. *Cancers*, **2021**, 13,	6.6	1
94	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. *Cancers*, **2021**, 13,	6.6	1
93	Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. *Pharmaceuticals*, **2021**, 14,	5.2	2
92	Hyperferritinemia-A Clinical Overview. *Journal of Clinical Medicine*, **2021**, 10,	5.1	9
91	Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. *Clinics and Practice*, **2021**, 11, 459-466	2.4	
90	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. *Journal of Personalized Medicine*, **2021**, 11,	3.6	2
89	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. *Hemato*, **2021**, 2, 607-627	0.2	0
88	Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine. *Current Medical Research and Opinion*, **2021**, 37, 2107-2111	2.5	
87	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. *SAGE Open Medical Case Reports*, **2021**, 9, 2050313X20988413	0.7	
86	Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity. *Cells*, **2020**, 9,	7.9	11
85	Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder. *Clinics and Practice*, **2020**, 10, 1214	2.4	2

84	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment. *Case Reports in Hematology*, **2020**, 2020, 1262038	0.7	0
83	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	55
82	Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. *Mediterranean Journal of Hematology and Infectious Diseases*, **2020**, 12, e2020009	3.2	19
81	Inhibition of NF-B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. *Cells*, **2020**, 9,	7.9	1
80	Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. *Transplantology*, **2020**, 1, 102-110	1	
79	Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. *Journal of Medical Case Reports*, **2020**, 14, 217	1.2	3
78	Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy. *Case Reports in Anesthesiology*, **2020**, 2020, 4219616	0.5	0
77	A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. *Journal of International Medical Research*, **2020**, 48, 300060520903660	1.4	3
76	Trisomy 8 in acute myeloid leukemia. *Expert Review of Hematology*, **2019**, 12, 947-958	2.8	13
75	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. *Signal Transduction and Targeted Therapy*, **2019**, 4, 20	21	26
74	Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. *Expert Opinion on Investigational Drugs*, **2019**, 28, 411-420	5.9	9
73	Precision medicine for TP53-mutated acute myeloid leukemia. *Expert Review of Precision Medicine and Drug Development*, **2019**, 4, 263-274	1.6	2
72	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. *Journal of Clinical Medicine*, **2019**, 8,	5.1	16
71	Mondor disease after extensive training with Nordic walking. *Oxford Medical Case Reports*, **2019**, 2019, omz075	0.6	
70	Severe nephritis as initial sign of Waldenstrm macroglobulinemia. *Clinics and Practice*, **2019**, 9, 1184	2.4	
69	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. *Expert Opinion on Investigational Drugs*, **2018**, 27, 377-387	5.9	17
68	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. *Cytotherapy*, **2018**, 20, 740-754	4.8	4
67	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. *Frontiers in Medicine*, **2018**, 5, 147	4.9	26

66	The Possible Importance of β Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	26
65	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	16
64	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 639-653	6.4	10
63	Successful eradication of leptomeningeal plasma cell disease. *Oxford Medical Case Reports*, **2018**, 2018, omy038	0.6	0
62	Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. *Case Reports in Hematology*, **2018**, 2018, 2045985	0.7	1
61	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. *Cancers*, **2018**, 10,	6.6	13
60	Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. *Vox Sanguinis*, **2018**, 113, 657-668	3.1	3
59	Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. *Case Reports in Oncological Medicine*, **2018**, 2018, 7697283	0.9	6
58	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. *Expert Review of Clinical Immunology*, **2017**, 13, 553-569	5.1	13
57	Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 357-369	6.4	16
56	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. *BMC Cancer*, **2017**, 17, 630	4.8	16
55	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. *Frontiers in Immunology*, **2017**, 8, 1979	8.4	7
54	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. *Expert Opinion on Drug Discovery*, **2017**, 12, 1053-1065	6.2	26
53	Microcirculation and red cell transfusion in patients with sepsis. *Transfusion and Apheresis Science*, **2017**, 56, 900-905	2.4	5
52	Non-curative surgery for aortoenteric fistula. *Journal of Surgical Case Reports*, **2017**, 2017, rjx153	0.6	3
51	CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors. *Molecules*, **2017**, 22,	4.8	7
50	Altered Immune Activation and IL-23 Signaling in Response to in Autoimmune Polyendocrine Syndrome Type 1. *Frontiers in Immunology*, **2017**, 8, 1074	8.4	3
49	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. *Metabolomics*, **2016**, 12, 12	4.7	22

48	Nutrition in Allogeneic Stem Cell Transplantion--Clinical Guidelines and Immunobiological Aspects. *Current Pharmaceutical Biotechnology*, **2016**, 17, 92-104	2.6	6
47	Myeloproliferative neoplasms and JAK2 mutations. *Tidsskrift for Den Norske Laegeforening*, **2016**, 136, 1889-1894	3.5	
46	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 3995-3995	2.2	1
45	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. *Frontiers in Immunology*, **2016**, 7, 205	8.4	22
44	Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	18
43	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. *Expert Review of Quality of Life in Cancer Care*, **2016**, 1, 373-387		3
42	Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. *Thrombosis Research*, **2015**, 136, 30-9	8.2	26
41	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. *Expert Review of Hematology*, **2015**, 8, 299-313	2.8	13
40	Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. *BMC Pharmacology & Toxicology*, **2015**, 16, 12	2.6	20
39	Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets. *Expert Review of Hematology*, **2015**, 8, 315-27	2.8	8
38	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. *Disease Markers*, **2015**, 2015, 943430	3.2	8
37	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. *Oncotarget*, **2015**, 6, 2794-811	3.3	12
36	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. *Stem Cell Research*, **2015**, 15, 530-541	1.6	41
35	The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples. *Journal of Immunological Methods*, **2015**, 418, 19-28	2.5	17
34	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. *Blood*, **2015**, 126, 4931-4931	2.2	
33	Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. *Cancer Immunology, Immunotherapy*, **2014**, 63, 757-77	7.4	29
32	Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 929-44	6.4	6
31	Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. *Journal of Transplantation*, **2014**, 2014, 404096	2.3	10

30	Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms. *Molecules*, **2014**, 19, 18414-47	4.8	57
29	Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. *Transfusion and Apheresis Science*, **2014**, 51, 97-102	2.4	22
28	Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. *British Journal of Haematology*, **2014**, 164, 200-11	4.5	33
27	Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. *SpringerPlus*, **2014**, 3, 571		14
26	Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 1237-51	6.4	17
25	Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation. *Blood Transfusion*, **2014**, 12, 50-5	3.6	9
24	The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine□he experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. *Toxins*, **2013**, 5, 336-62	4.9	24
23	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. *Expert Opinion on Investigational Drugs*, **2013**, 22, 551-63	5.9	24
22	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. *Current Cancer Drug Targets*, **2013**, 13, 30-47	2.8	10
21	Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. *Oncotarget*, **2013**, 4, 830-43	3.3	39
20	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. *Blood*, **2013**, 122, 2625-2625		1
19	Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. *Current Cancer Drug Targets*, **2013**, 13, 30-47	2.8	6
18	Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. *American Journal of Hematology*, **2012**, 87, 368-76	7.1	28
17	The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. *Platelets*, **2012**, 23, 299-308	3.6	11
16	The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 190-9	4.7	26
15	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. *European Journal of Haematology*, **2012**, 89, 478-90	3.8	13
14	Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?. *Expert Opinion on Investigational Drugs*, **2012**, 21, 587-603	5.9	20
13	Questionnaire-related deferrals in regular blood donors in norway. *Journal of Blood Transfusion*, **2012**, 2012, 813231		2

List of Publications

12	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. *British Journal of Haematology*, **2012**, 156, 468-80	4.5	35
11	The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. *European Cytokine Network*, **2012**, 23, 140-53	3.3	34
10	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. *European Cytokine Network*, **2011**, 22, 52-62	3.3	14
9	Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia. *Journal of Proteomics*, **2011**, 74, 269-81	3.9	5
8	Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 104631		48
7	The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. *Current Topics in Microbiology and Immunology*, **2010**, 341, 149-72	3.3	36
6	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. *Expert Opinion on Investigational Drugs*, **2010**, 19, 169-83	5.9	28
5	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. *European Journal of Haematology*, **2010**, 84, 239-51	3.8	42
4	The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. *Blood Transfusion*, **2010**, 8, 186-92	3.6	26
3	Targeted therapy in acute myeloid leukaemia: current status and future directions. *Expert Opinion on Investigational Drugs*, **2009**, 18, 433-55	5.9	31
2	Thrombelastography. *Transfusion and Apheresis Science*, **2009**, 40, 119-23	2.4	113
1	Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. *Critical Reviews in Oncogenesis*, **2009**, 15, 1-41	1.3	39